
Author(s) and Collaborator(s): Please identify all author(s) and collaborator(s), their affiliations, and their disclosures.

- James Valentine, JD, MHS, Associate, Hyman, Phelps & McNamara, P.C.
- Margaret Wahl, R.N., independent contractor
- Molly White, Chief Executive Officer, Myotonic Dystrophy Foundation
- Al Nazarelli, President & CEO, Silicon Valley Research Group; project lead on the Benefit Risk Study report provided in the VOP Report appendix

Disclosures: MDF received no funding from pharmaceutical companies, industry or other sources for the Myotonic Dystrophy Externally-Led PFDD Meeting. The Foundation paid for all direct costs associated with the meeting. Ionis Pharmaceuticals provided in-kind facilitation and project development support through the services of James Valentine, JD.

Funding Received or Granted: MDF received no funding for this project. In-kind support in the form of James Valentine’s participation in project development and meeting facilitation was provided by Ionis Pharmaceuticals.

Version Date: April 2017

Voice of the Patient: A Report from the Myotonic Dystrophy Externally-Led Patient-Focused Drug Development Meeting has not been revised and/or modified in any way after the version date listed above.

The authors have the necessary permissions to submit the resource to the FDA. Linking from the FDA website will not violate the proprietary rights of others.

Point of contact: Molly White, Chief Executive Officer, Myotonic Dystrophy Foundation; molly.white@myotonic.org